Treace Medical Concepts, Inc. (TMCI) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$13.07M*; Operating income -$14.96M; Depreciation and amortization $1.89M*.
- 2026-03-31: Basis Reported; EBITDA -$16.27M*; Operating income -$17.17M; Depreciation and amortization $899.00K.
- 2025-09-30: Basis Reported; EBITDA -$12.90M*; Operating income -$15.68M; Depreciation and amortization $2.78M*.
- 2025-06-30: Basis Reported; EBITDA -$14.40M*; Operating income -$16.97M; Depreciation and amortization $2.58M*.
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | -$13.07M* | -$14.96M | $1.89M* | (m) | (m) | $2.20M* | -$4.70M* | $9.77M | $4.38M | (m) | (m) |
| 2026-03-31 | Reported | -$16.27M* | -$17.17M | $899.00K | (m) | (m) | $3.06M | $7.24M | $9.79M | $4.62M | (m) | (m) |
| 2025-09-30 | Reported | -$12.90M* | -$15.68M | $2.78M* | (m) | (m) | $2.81M* | -$9.09M* | $10.51M | $4.68M | (m) | (m) |
| 2025-06-30 | Reported | -$14.40M* | -$16.97M | $2.58M* | (m) | (m) | $4.77M* | -$3.05M* | $9.63M | $5.50M | (m) | (m) |
| 2025-03-31 | Reported | -$13.12M* | -$15.58M | $2.46M | (m) | (m) | $3.54M | $4.20M | $10.68M | $5.56M | (m) | (m) |
| 2024-09-30 | Reported | -$12.98M* | -$15.13M | $2.16M* | (m) | (m) | $2.86M* | -$11.84M* | $8.95M | $4.96M | (m) | (m) |
| 2024-06-30 | Reported | -$19.27M* | -$21.38M | $2.12M* | (m) | (m) | $1.73M* | -$13.90M* | $8.78M | $5.16M | (m) | (m) |
| 2024-03-31 | Reported | -$17.06M* | -$18.97M | $1.91M | (m) | (m) | $3.93M | -$7.22M | $10.13M | $5.26M | (m) | (m) |
| 2023-09-30 | Reported | -$16.25M* | -$17.82M | $1.56M* | (m) | (m) | $3.50M* | -$9.51M* | $8.00M | $4.35M | (m) | (m) |
| 2023-06-30 | Reported | -$11.95M* | -$13.05M | $1.10M | (m) | (m) | $4.23M* | -$8.34M* | $7.67M | $3.53M | (m) | (m) |
| 2023-03-31 | Reported | -$12.85M* | -$13.78M | $924.00K | (m) | (m) | $1.48M | -$17.26M | $8.04M | $3.41M | (m) | (m) |
| 2022-09-30 | Reported | -$10.92M* | -$11.32M | $400.00K | (m) | (m) | $5.86M* | -$7.48M* | $6.09M | $3.80M | (m) | (m) |
| 2022-06-30 | Reported | -$11.53M* | -$11.93M | $400.00K | (m) | (m) | $5.17M* | -$10.57M* | $5.29M | $2.98M | (m) | (m) |
| 2022-03-31 | Reported | -$7.76M* | -$8.10M | $334.00K | (m) | (m) | $1.48M | -$7.24M | $5.13M | $3.05M | (m) | (m) |
| 2021-09-30 | Reported | -$5.26M* | -$5.46M | $200.00K | (m) | (m) | $939.00K* | -$9.26M* | $4.25M | $2.54M | (m) | $0.00 |
| 2021-06-30 | Reported | -$3.95M* | -$4.05M | $100.00K | (m) | (m) | $670.00K* | -$3.73M* | $3.94M | $2.42M | (m) | $0.00 |
| 2021-03-31 | Reported | -$1.28M* | -$1.40M | $117.00K | (m) | (m) | $196.00K | -$446.00K | $3.33M | $1.87M | (m) | $0.00 |
| 2020-09-30 | Reported | $237.00K* | -$63.00K | $300.00K | (m) | (m) | $58.00K* | -$4.20M* | $2.91M | $1.51M | (m) | $0.00 |
| 2020-06-30 | Reported | -$1.12M* | -$1.52M | $400.00K | (m) | (m) | $249.00K* | -$1.84M* | $2.08M | $982.00K | (m) | $0.00 |
| 2020-03-31 | Reported | -$895.00K* | -$1.20M | $304.00K | (m) | (m) | $674.00K | -$895.00K | $2.39M | $1.43M | (m) | $0.00 |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | -$43.53M* | -$54.15M | $10.62M | (m) | (m) | $13.52M | -$15.97M | $42.94M | $20.28M | (m) | $0.00 |
| 2024-12-31 | Reported | -$47.27M* | -$55.69M | $8.42M | (m) | (m) | $11.59M | -$37.17M | $41.09M | $20.59M | (m) | $0.00 |
| 2023-12-31 | Reported | -$46.08M* | -$51.43M | $5.35M | (m) | (m) | $11.46M | -$34.58M | $35.18M | $15.44M | (m) | $0.00 |
| 2022-12-31 | Reported | -$32.71M* | -$34.84M | $2.13M | (m) | (m) | $14.84M | -$30.65M | $25.53M | $13.58M | (m) | $0.00 |
| 2021-12-31 | Reported | -$15.82M* | -$16.51M | $685.00K | (m) | (m) | $2.71M | -$17.19M | $16.89M | $10.20M | (m) | $0.00 |
| 2020-12-31 | Reported | $2.06M* | $855.00K | $1.21M | (m) | (m) | $1.07M | -$4.49M | $12.47M | $5.85M | (m) | $0.00 |
| 2019-12-31 | Reported | -$2.74M* | -$3.54M | $793.00K | (m) | (m) | $1.21M | -$7.67M | $7.63M | $5.07M | (m) | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |